BRIEF-Maat Pharma Says Maat033 Shows Favorable Safety Profile And Tolerability

Oct 7 (Reuters) – Maat Pharma SA: * MAAT PHARMA ANNOUNCES POSITIVE SECOND SAFETY INTERIM ANALYSIS FROM DSMB FOR PHASE 2B PHOEBUS TRIAL EVALUATING MAAT033 FOR PATIENTS RECEIVING ALLO-HSCT * MAAT PHARMA SA – MAAT033 SHOWS FAVORABLE SAFETY PROFILE AND TOLERABILITY

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)